BioPhorum blazes a trail tackling your buffer preparation bottlenecks

Buffers are critical inputs into all downstream processing steps associated with the manufacture of therapeutic proteins. The large volumes of buffer required present ongoing logistical challenges and account for a significant portion of a facility’s footprint, labor requirements and equipment costs.

The first edition Biomanufacturing Technology Roadmap identified the improvement of buffer management as a key strategic need for the industry. A BioPhorum collaboration of leading biopharmaceutical companies, engineering firms and suppliers has therefore been working together for 18 months to meet this need.

It developed a design for a Buffer Stock Blending (BSB) System to support the preparation of buffers in-line and on demand from concentrated single-component stock solutions. The collaboration on a user requirements specification fueled a desire to prototype the design and the team obtained funding from NIIMBL1 to build the skid with vendors IPEC and Pieper Automation.

 

The NIIMBL-BioPhorum Buffer Stock Blending (BSB) System

The functional specification has been signed off and the vendors are moving into the build phase. The team is now preparing for factory acceptance testing, delivery of the Buffer Stock Blending (BSB) System to NIIMBL’s laboratory at the University of Delaware, performance testing and the subsequent release of the design and dataset.

The team has also recently published two white papers. The first, NIIMBL-BioPhorum Buffer Stock Blending System: A More Advanced Concept for Buffer Manufacturing, describes the project and activities up to the award of the contract to IPEC, and explains the industry drivers for change and the team’s approach to buffer preparation. The second paper, An Economic Evaluation of Buffer Preparation Philosophies for the Biopharmaceuticals Industry, is a deep-dive into some of the modeling work done to support the project.

The team is now writing a realization protocol that it will execute. This will establish that the Buffer Stock Blending (BSB) System is capable of supplying the buffers required by typical purification processes, at a quality that is acceptable and equivalent to traditional batch buffer preparation.

The dataset will then be evaluated alongside further modeling data to demonstrate that the design has achieved the expected benefits, and an addendum to the first white paper will be published in the first half of 2020.

The benefits

To ensure the supply of buffers needed for the manufacture of biotherapeutic products, particularly with an expected increase in upstream productivity, Nathalie Frau (Head Biologics Technology Innovation & Strategy – Downstream Processing at Sanofi) said the industry needs to address the exponential challenges it will face regarding facility footprints, labor requirements, capital costs and logistics.

“The implementation of an automated in-line buffer manufacturing system can significantly reduce capital and operating costs, and minimize the volume of buffers to be prepared per batch, the number of buffers to be prepared and the associated labor,” said Frau. “This technology also offers the possibility to purchase standardized, ready-to-use, concentrated and single-component stock solutions to connect them directly to the buffer manufacturing system.”

For example, the move to single-use bags of less than 2,000L instead of large stainless steel tanks (often more than 12,000L), could create potential savings of more than $20m per facility built. Labor requirements will also be significantly reduced and buffer preparation can be cut from a 3×7-day operation to a 1×5-day operation in each facility.

The technology also has the potential to enable the transition from a predominately stainless steel facility, common today, to a predominately single-use facility of the future, with the potential to deliver a capital reduction of more than $100m for each new facility.

BioPhorum has blazed a trail on this project with some key initiatives:

  • Industry collaboration on requirements (BioPhorum)
  • Using an open architecture – anyone can build and improve it
  • Successful consortium (including NIIMBL) to build and test the prototype.

By mid-2020, the project will deliver a fully tested and documented approach to buffer preparation while driving industry adoption through an open-source approach to the publication of the design and dataset.

For more information on the Buffer Preparation project and the NIIMBL-BioPhorum Buffer Stock Blending (BSB) System, please contact Danièle Wiseman on daniele@biophorum.com

[1] This work was performed under financial assistance award 70NANB17H002 from the US Department of Commerce, National Institute of Standards and Technology.

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

How the fast-start C&GT Phorum is delivering results

From a standing start in 2018, the BioPhorum Cell & Gene Therapy (C>) Phorum has made huge progress on a range of initiatives aimed at[...]

Read More
Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
Sharing powerful collaboration data on the impact of resin cycling on viral clearance

A crucial issue for biotechnology products is that the mammalian cell lines commonly used in manufacturing are susceptible to viral contamination. Therefore, demonstration of viral[...]

Read More
Industry bioassay approach helps to shape the future

In 2018, members of the Development Group Bioassay workstream came together to write a best practices paper on bioassay development. We are delighted to announce[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
BioPhorum Anvisa support goes from strength to strength

There are many things that make a relationship work, such as trust, honesty and mutual respect. And a sign of a strong relationship is someone[...]

Read More
Delivering globally on in-line monitoring and real-time release

BioPhorum is increasing its focus on delivering against strategic goals of member companies as outlined in the BioPhorum Biomanufacturing Technology Roadmap. The first step in[...]

Read More
New and improved User Requirements Toolkit for single-use systems

To help customers and manufacturers achieve a ‘right first time’ implementation of single-use systems, BioPhorum launched a User Requirements Toolkit in June 2018. This includes[...]

Read More
PUPSIT – An update on BioPhorum/PDA work to develop a risk-based position
Read More
Driving the evolution of secondary packaging

How do we transition from large-batch manufacture to small-batch, high-value packaging runs?

Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Logistics collaboration hub: An opportunity for significant time and cost savings

Most biopharmaceutical manufacturers use a network of logistics service providers (LSPs) to deliver warehousing, transport and distribution services, and they are usually linked using customized,[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
BioPhorum’s Maturity Assessment Tool gains momentum
Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
BioPhorum blazes a trail tackling your buffer preparation bottlenecks

Buffers are critical inputs into all downstream processing steps associated with the manufacture of therapeutic proteins. The large volumes of buffer required present ongoing logistical[...]

Read More
How plug-and-play will help you glide through the biomanufacturing dance

It is pretty clear that automation can improve efficiency, track performance and liberate operators from mundane routines. But with it comes cost and time factors[...]

Read More
Delivering globally on in-line monitoring and real-time release

BioPhorum is increasing its focus on delivering against strategic goals of member companies as outlined in the BioPhorum Biomanufacturing Technology Roadmap. The first step in[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
Regulatory compliance: what lessons can be learned?

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Changes to BioPhorum extractables protocol

The BioPhorum Extractables team has shown the benefits of great collaboration between biomanufacturers and suppliers – they agreed to significantly reduce extractables testing for single use[...]

Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More
New and improved User Requirements Toolkit for single-use systems

To help customers and manufacturers achieve a ‘right first time’ implementation of single-use systems, BioPhorum launched a User Requirements Toolkit in June 2018. This includes[...]

Read More
BioPhorum blazes a trail tackling your buffer preparation bottlenecks

Buffers are critical inputs into all downstream processing steps associated with the manufacture of therapeutic proteins. The large volumes of buffer required present ongoing logistical[...]

Read More
How plug-and-play will help you glide through the biomanufacturing dance

It is pretty clear that automation can improve efficiency, track performance and liberate operators from mundane routines. But with it comes cost and time factors[...]

Read More
BioPhorum Anvisa support goes from strength to strength

There are many things that make a relationship work, such as trust, honesty and mutual respect. And a sign of a strong relationship is someone[...]

Read More

Share This

Share this

Share this post with your colleagues.